Publicaciones en colaboración con investigadores/as de Brigham and Women's Hospital (12)

2024

  1. The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers

    Journal of Clinical Investigation, Vol. 134, Núm. 8

2019

  1. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628

  2. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 12, pp. 899-911

  3. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

    The Lancet, Vol. 394, Núm. 10204, pp. 1169-1180

2018

  1. Alirocumab and cardiovascular outcomes after acute coronary syndrome

    New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107

  2. Meta-analysis of Immunochip data of four autoimmune diseases reveals novel single-disease and cross-phenotype associations

    Genome Medicine, Vol. 10, Núm. 1

2017

  1. Cardiovascular efficacy and safety of bococizumab in high-risk patients

    New England Journal of Medicine, Vol. 376, Núm. 16, pp. 1527-1539

  2. Expert Statement on the Single-Agent Use of Inhaled Bronchodilator in the Treatment of Stable Mild-Moderate Chronic Obstructive Pulmonary Disease

    Archivos de Bronconeumologia, Vol. 53, Núm. 10, pp. 574-582

2016

  1. Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

    Journal of the American Heart Association, Vol. 5, Núm. 9

2015

  1. TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumor necrosis factor therapy

    BioMed Research International, Vol. 2015

2013

  1. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

    New England Journal of Medicine, Vol. 369, Núm. 14, pp. 1317-1326

2003

  1. Analysis of metabolic parameters as predictors of risk in the RENAAL study

    Diabetes Care, Vol. 26, Núm. 5, pp. 1402-1407